Volume | 449,136 |
|
|||||
News | - | ||||||
Day High | 18.15 | Low High |
|||||
Day Low | 17.44 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Silk Road Medical Inc | SILK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
17.65 | 17.44 | 18.15 | 17.80 | 17.65 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
8,128 | 449,136 | US$ 17.79 | US$ 7,990,158 | - | 6.08 - 45.085 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:25:33 | 1 | US$ 17.82 | USD |
Silk Road Medical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
698.48M | 39.17M | - | 177.13M | -55.74M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Silk Road Medical News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SILK Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.39 | 18.15 | 16.40 | 17.53 | 629,562 | 0.41 | 2.36% |
1 Month | 18.32 | 19.28 | 16.40 | 17.68 | 469,892 | -0.52 | -2.84% |
3 Months | 15.24 | 22.52 | 14.84 | 17.17 | 750,909 | 2.56 | 16.80% |
6 Months | 6.20 | 22.52 | 6.08 | 13.02 | 881,727 | 11.60 | 187.10% |
1 Year | 44.64 | 45.085 | 6.08 | 16.53 | 942,773 | -26.84 | -60.13% |
3 Years | 58.27 | 67.49 | 6.08 | 29.08 | 559,669 | -40.47 | -69.45% |
5 Years | 38.15 | 75.80 | 6.08 | 33.96 | 471,710 | -20.35 | -53.34% |
Silk Road Medical Description
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk. |